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We studied whether grey matter network parameters are associated with rate of clinical 
progression in non-demented subjects who have abnormal amyloid markers in the 
cerebrospinal fluid (CSF), i.e., pre-dementia AD. Non-demented subjects (62 with 
subjective cognitive decline; 160 with mild cognitive impairment; age = 68±8 years; MMSE 
= 28±2.4) were selected from the Amsterdam Dementia Cohort when they had abnormal 
amyloid CSF levels (<640 pg/ml). Networks were extracted from grey matter structural 
MRI, and nine parameters were calculated. Cox proportional hazards models were used to 
test associations between each connectivity predictor and the rate of progression to mild 
cognitive impairment or dementia. After a median time of 2.2 years (1.4-3.1), 122 (55%) 
subjects showed clinical progression. Lower network parameter values were associated with 
increased risk for progression, with the strongest Hazard Ratio of 0.29 for clustering (95%CI 
=0.12 - 0.70; p<.01). Results remained significant after correcting for tau, hippocampal 
volume and MMSE scores. Our results suggest that at pre-dementia stages, grey matter 
networks parameters may have use to identify subjects who will show fast clinical 
progression. 
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Accumulation of amyloid in the brain is among the first changes leading to Alzheimer's 
disease (AD)(Sperling et al., 2011; Toledo et al., 2015; van Harten et al., 2013). Future disease 
modifying therapies are probably most effective in the earliest stages of AD, to prohibit the 
pathological cascade of events leading to dementia from unfolding. Prognostic biomarkers 
that can be used to predict time to clinical progression are necessary for disease 
management, as well as therapy development. Once amyloid is abnormal, it is only weakly 
related to the rate of clinical progression, probably because it reaches plateau levels at early, 
preclinical stages of the disease (Jack et al., 2013). Alternative biomarkers are needed that 
show a better relationship with cognitive decline. 
 
Soluble beta amyloid oligomers and the deposition of amyloid beta into insoluble plaques 
disrupt synaptic functioning, and loss of synapses has been robustly associated with signs 
and symptoms of dementia (Selkoe, 2002). Synaptic dysfunction impacts on brain 
connectivity, and so it can be hypothesised that brain connectivity as measured with 
neuroimaging techniques might be a sensitive marker for incipient brain damage. One way 
to measure brain connectivity is based on patterns of coordinated grey matter morphology 
from structural MRI (Alexander-Bloch et al., 2013a; Bassett et al., 2008; Lerch et al., 2006; 
Mechelli et al., 2005; Tijms et al., 2012). Coordinated patterns of grey matter morphology have 
been associated with functional co-activation (Alexander-Bloch et al., 2013b; Andrews et al., 
1997), axonal connectivity (Gong et al., 2012),  and/or genetic factors (Chen et al., 2013; 
Schmitt et al., 2009). In AD grey matter networks seem to be more randomly organised, as 
indicated e.g., by a lower value of the small world coefficient (Friedman et al., 2015; Li et al., 
2012; Pereira et al., 2016; Phillips et al., 2015; Tijms et al., 2013a; 2014; Yao et al., 2010; Zhou and 
Lui, 2013). We previously have shown that worse grey matter network disruptions are 
associated with worse disease severity and cognitive dysfunction (Tijms et al., 2014; 2013a). 
 
A recent study reported that grey matter network parameters in subjects with mild cognitive 
impairment (MCI) who later progressed to dementia were more similar to the organisation 
of grey matter networks in AD subjects, than those of controls (Pereira et al., 2016). In 
cognitively normal elderly, disruptions of grey matter networks have been associated with 
more abnormal amyloid-beta 1-42 (Aβ 1-42) levels in cerebrospinal fluid (CSF), suggesting 
that grey matter network measures are sensitive to pathological changes at very early stages 
of AD (Tijms et al., 2016). However, it remains unclear if grey matter network parameters are 
associated with rate of clinical progression in pre-dementia AD. 
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In this study, we investigated the hypothesis that grey matter network disruptions are 
associated with time to clinical progression in a memory clinic sample of subjects with 
subjective cognitive decline (SCD) or MCI and abnormal amyloid CSF markers. Based on 
previous studies we expected that indications of a more randomly organised network would 




For the COnnectivity in DementiA (CODA) study we selected 62 subjects with SCD and 
160 subjects with MCI from the Amsterdam Dementia Cohort(van der Flier et al., 2014) 
when they had abnormal Aβ 1-42 CSF levels (<640 pg/ml; see section 2.4 for details of CSF 
analysis), baseline T1-weighted structural MRI and at least 1 year clinical follow-up data 
available. Subjects initially visited our memory clinic at the Alzheimer Centre of the VU 
University Medical centre between 2000 and 2014. Most subjects underwent standard 
dementia screening that included a medical history, physical and neurological examination, 
extensive neuropsychological evaluation, screening laboratory tests, an 
electroencephalogram and an MRI scan. Subjects were diagnosed during a multidisciplinary 
consensus meeting with SCD when they presented with cognitive complaints, but cognitive 
and laboratory investigations were normal and they did not meet criteria for MCI, dementia 
or any other neurological disorder (Jessen et al., 2014); or with MCI when they fulfilled 
corresponding criteria (Albert et al., 2011; Petersen et al., 1999). For most subjects follow-
up visits were part of the regular care, scheduled at about 1 year intervals and included 
medical history, neurological and neuropsychological work up. Clinical progression was 
defined as receiving a follow-up diagnosis of MCI or AD-dementia, made in a 
multidisciplinary meeting based on commonly used criteria (Albert et al., 2011; McKhann et 
al., 1984; McKhann et al., 2011; Petersen et al., 1999). The primary outcome measure in the 
present study was time to clinical progression, defined as the time between the baseline MRI 




2.2 MRI acquisition and preprocessing 
High resolution 3D T1-weighted structural images were acquired as part of routine subject 
care. Over the years, scans were acquired from 7 different MRI scanners (see supplementary 
material for acquisition details). The distribution of scanner types did not differ between 
subjects who showed progression and who remained stable (p>.05; S-table 1). An 
experienced neuroradiologist reviewed all scans for brain pathology other than atrophy. 
Scans were segmented into cerebrospinal fluid, grey and white matter using Statistical 
Parametric Mapping Software version 12 (SPM12; Functional Imaging Laboratory, 
University College London, London, UK) run in Matlab 7.12 (MathWorks, Natick, MA). 
For each subject, 90 brain areas were identified in the native space grey matter 
segmentations with the use of the Automated Anatomical Labelling Atlas (AAL; (Tzourio-
Mazoyer et al., 2002), by warping the AAL atlas from standard space to subject space using 
inverted parameters that had been calculated for non-linear normalisation of subject images 
to standard MNI space. Total intracranial volume was calculated as the sum of grey matter, 
white matter and cerebrospinal fluid voxels from the native space segmentations. Native 
grey matter segmentations were resliced into 2mm
3
 isotropic voxels to ensure equal voxel 
sizes across all scans. 
 
2.3 Grey matter networks 
Single-subject grey matter networks were extracted from native space grey matter density 
segmentations using a fully automated method previously described in detail 
(https://github.com/bettytijms/ Single_Subject_Grey_Matter_Networks; (Tijms et al., 2012). 
Briefly, this method determines whether small regions of interest (defined as 3x3x3 voxel 
cubes containing grey matter density estimates) show statistical similarity as quantified with 
Pearson’s correlations. A network is constructed by connecting brain areas when the 
significance of their correlations values exceeds a threshold of p <.05 corrected for multiple 
testing based on permutation testing. Table 1 gives an overview of the network properties 
that were computed at the node and/or global level for each network: the degree (i.e., the 
number of edges of a node), characteristic path length (i.e., the minimum number of edges 
between any pair of nodes), clustering coefficient (i.e., the level of interconnectedness 
between the neighbours of a node), and betweenness centrality (i.e., the proportion of 
characteristic paths that run through a node). In addition, the size of the network is the 
number of nodes in a network, and connectivity density is the proportion of existing edges to 
the total number of edges possible. To estimate normalised path length λ and normalised 
clustering coefficient γ, we averaged the characteristic path length and clustering coefficient 
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across the nodes for each network and then divided these properties by those that were 
averaged across 20 randomised reference networks that had an identical size and degree 
distribution (Maslov and Sneppen, 2002). A network is considered to be ‘small world’ when γ/ 
λ > 1. Network properties were computed with scripts from the Brain Connectivity Toolbox 
that we modified for large sized networks (www.brain-connectivity-toolbox.net, (Rubinov 
and Sporns, 2010). In order to reduce dimensionality when comparing local network 
properties, we averaged network property values across nodes within each of the 90 AAL 
areas. 
======== Please insert table 1 about here ======= 
 
2.4 Cerebrospinal fluid analysis 
CSF samples were obtained with a lumbar puncture between the L3/L4, L4/L5 or L5/S1 
intervertebral space using a 25-gauge needle and syringe and collected in polypropylene 
tubes. Biomarker values were determined at the Neurochemistry laboratory of the 
department of Clinical Chemistry of the VUmc. Aβ 1-42 and total tau concentrations were 
determined with sandwich ELISAs (Innotest, Belgium) (Mulder et al., 2010). Subjects were 
classified as harbouring abnormal amyloid when CSF Aβ 1-42 levels were lower than 640 
pg/mL (Zwan et al., 2014). 
 
2.5 Statistical analyses 
Demographical and clinical characteristics were compared between subjects who remained 
stable and those who showed clinical progression over time with t-tests, Kruskal-Wallis tests 
or chi-square tests when appropriate. Baseline network measures were compared for clinical 
outcome with ANCOVAs, taking into account an interaction effect of baseline cognitive 
status (SCD or MCI), and as covariates age, gender, normalised whole brain grey matter 
volume (i.e, grey matter volume divided by total intracranial volume), and scanner type. We 
used Cox proportional hazards models to assess for each of the 9 global grey matter network 
measures (predictor variables, i.e, size, degree, connectivity density, clustering coefficient, 
path length, betweenness centrality, γ, λ and the small world metric) associations with time 
to clinical progression (dependent variables). All network measures were Z-transformed to 
aid interpretation of Hazard Ratios (HR). We ran four models: Model 1 included covariates 
age, gender, normalised whole brain grey matter volume, MRI scanner type and baseline 
cognitive status (SCD or MCI). Model 2 added CSF tau levels as additional covariate to 
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Model 1. Model 3 added hippocampal volume (obtained from the AAL parcellation of grey 
matter) as an additional covariate to Model 2. Model 4 added MMSE scores as an additional 
covariate to Model 3. If size, average degree or connectivity density showed a significant 
main effect it was included as an additional covariate, because these properties are known to 
influence other network properties (van Wijk et al., 2010). Cox proportional hazards analyses 
were repeated for local network properties in each of the 90 AAL areas, with additional 
correction for local grey matter volume. Global and local analyses were corrected for 
multiple comparisons with the false discovery rate (FDR) procedure (Benjamini and Yekutieli, 




3.1 Sample description 
After a median time of 2.2 years, 122 subjects showed clinical progression: 18 to mild 
cognitive impairment, 96 to AD dementia and nine to other types of dementia (table 2). 
Compared to subjects who remained stable, those who showed clinical progression more 
often had MCI, were older, had lower MMSE scores, higher CSF tau levels and less 
normalised whole brain grey matter volume. Stable and progressive subjects had a similar 
follow up time (p>.05). None of the grey matter networks had disconnected nodes and the 
average connectivity density was 16% (SD = 1.26%). 
======== please insert Table 2 about here ======= 
 
3.2 Grey matter network measures and clinical outcome in pre-dementia AD 
Network size, degree and connectivity density were comparable between subjects who 
remained stable and those who progressed (table 2). Compared to subjects who remained 
stable, subjects who progressed had lower γ and small world values. At a local level, 
subjects who progressed had lower clustering coefficient values in several anatomical areas, 
but only the left orbitofrontal cortex survived correction for multiple hypothesis testing 
(F(1,211) = 15.34, pFDR = 0.01). No interaction effects for baseline cognitive status were 
found, which suggests that lower γ and small world values associated with clinical 
progression were similar for subjects with SCD and MCI. 
 
3.3 Grey matter network measures and time to clinical progression 
Table 3 shows that the HRs of most network properties were below 1, with lower HRs 
indicating that per standard deviation decrease in the values of degree, connectivity density, 
the clustering coefficient, path length, γ, λ and the small world property at baseline, the risk 
of clinical progression increases. Clustering coefficient values showed the lowest HR, with 
lower values being associated with a 3-fold increased risk for clinical progression (HR = 
0.29; 95%CI =0.12 - 0.70, p = .006, pFDR = .02). For illustrative purposes, figure 1 shows the 
clinical outcome for connectivity density, clustering and γ according to tertiles. Results 
remained largely unchanged after correcting for baseline CSF tau levels, hippocampal 
volume and MMSE scores (table 3). Interaction terms of baseline cognitive status and grey 
matter networks measures on the time to clinical progression were not significant (all 




Repeating cox proportional hazards analyses for regional network values, additionally 
correcting for local grey matter volume, showed that the association of lower clustering 
values and time to progression were specific for the right precuneus, left hippocampus and 
right angular gyrus, occipital areas and the right supramarginal gyrus were associated with 
time to clinical progression (figure 2). These local associations were subtle however, as none 
of the local proportional hazards analyses survived correction for multiple testing. 
 
======== Please insert Table 3 about here ======= 
======== Please insert figure 1 about here ======= 





The main finding of the present study is that in subjects with pre-dementia AD alterations of 
grey matter network parameters at baseline were associated with faster clinical progression. 
In these subjects, lower values for degree, clustering, normalised clustering, normalised path 
length and the small world property, indicative for a more randomly organised network, 
were associated with clinical outcome and predicted faster clinical progression. Regional 
analyses suggested that clustering values were lower in specific anatomical areas, 
comprising mostly temporal and frontal lobes. HRs remained largely unchanged after 
additional correction for CSF tau, and hippocampal volume, suggesting that grey matter 
network properties have additive value over these more conventional biomarkers. Together, 
these results provide further support for the hypothesis that disruptions in brain connectivity 
underlie cognitive decline. 
 
Subjects showing clinical progression over time had lower values for clustering, normalised 
clustering and the small world property. This suggests that their grey matter networks are 
organised more like that of a random network, and as such seem to move towards a network 
organisation that has previously been reported for AD subjects (Li et al., 2012; Pereira et al., 
2016; Phillips et al., 2015; Tijms et al., 2014; 2013a) (but also see (Yao et al., 2010) reporting 
higher clustering in AD and MCI compared to controls). This supports the idea that 
disruptions in grey matter networks start before the dementia stage of the disease and as 
such might be sensitive to early changes in brain structural integrity, and are closely related 
to future cognitive decline. 
 
Associations between lower clustering values and faster decline were found to be specific 
for several anatomical areas including the inferior parietal gyrus, occipital areas, 
hippocampus and the precuneus, even when additionally correcting for local grey matter 
volume. Most of these areas have previously been reported in grey matter network studies to 
be associated with AD (He et al., 2008; Tijms et al., 2014; 2013a; 2013b; Yao et al., 2010). The 
largest difference in local clustering associated with clinical progression was found in the 
orbitofrontal cortex that is part of the functionally defined ‘default mode’ network, which 
seems particularly vulnerable for AD pathology (Buckner et al., 2009). This area is also 
among brain areas reported to show increased rates of amyloid plaques accumulation 
subjects with an initially abnormal amyloid positron emission tomography (PET) scan 
(Villain et al., 2012). A recent study showed that compared to controls, MCI subjects showing 
clinical progression had reduced clustering in the right postcentral gyrus (Pereira et al., 2016). 
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Another study investigating grey matter networks based on correlating rates of change in 
cortical thickness over time between brain areas, demonstrated improved classification 
accuracy when differentiating between mild cognitive impairment subjects who remained 
stable and who progressed over time when the clustering coefficient was included (Li et al., 
2012). In particular, clustering coefficient values of the parahippocampal gyrus, temporal 
lobe and supramarginal gyrus showed the best discriminatory value between groups of 
stable and progressive subjects (Li et al., 2012). Another study using a similar longitudinal 
approach(Friedman et al., 2015) showed that network structure in mild cognitive impairment 
subjects who later progressed to dementia due to AD became increasingly more randomly 
organised over time. Here we further extend these findings, by showing that grey matter 
network parameters based on a single baseline measurement are associated with faster 
clinical progression within amyloid positive subjects. 
 
A potential limitation of the present study is that due to the long period of time during which 
we were able to retrospectively include subjects, scans were obtained from 7 different 
scanners that varied in manufacturers and field strengths between 1 and 3T. The use of 
different scanners might have introduced noise in the data, although it is unlikely that this 
has biased the present results since stable and progressive subjects showed similar scanner 
type distributions and scanner type was included as a covariate in the analyses. 
 
In conclusion, in the pre-dementia phases of AD grey matter network alterations can be 
observed that are suggestive of a change towards a more random network organisation and 
these alterations seem to predict faster clinical progression. Based on abnormal amyloid, 
about 50% of pre-dementia AD individuals will develop dementia within a 3-year period. 
Hence, additional markers are necessary to identify individuals who will progress within 
e.g., a 1-year period. Here we show that grey matter network parameters might be useful to 
identify fast progressing subjects, and that in particular the small world property has additive 
value over more conventionally used biomarkers CSF tau levels and hippocampal volume. 
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Figure Legends and Tables 
 
Figure 1. Clinical progression curves for the time to dementia onset in subjects with 
subjective cognitive decline or mild cognitive impairment for connectivity density, 
clustering and normalised clustering according to tertiles, adjusted for age, gender, total 
brain volume, baseline cognitive status and MRI scanner. Clustering and γ were additionally 
adjusted for connectivity density. Blue lines represent subjects with network property values 
in the highest tertile, orange with intermediate values and red line with the lowest values. 
 
Figure 2. Surface plots of the AAL areas where reduced clustering was associated with time 
to progression in pre-dementia Alzheimer’s disease subjects. Reduced clustering was 
associated with time to progression in right supramarginal gyrus, bilateral middle occipital 
gyrus, right postcentral gyrus, left Heschl’s gyrus, left hippocampus, right angular gyrus, 
right inferior frontal triangularis, right precuneus. All analyses were adjusted for age, 




Table 1. Overview of studied network properties. 
Network measure Global, local Explanation Example 
1. Network size Global Total number of nodes (i.e., brain areas).  
2. Connectivity 
density  
Global Percentage observed connections from 
the maximum number possible 
connections. 
 
3. Degree Global, local The number of connections per node  
4. Clustering 
coefficient 
Global, local Proportion existing connections between 
neighbouring nodes from maximum 
number possible connections. This is a 
measure of information segregation, i.e., 
specialised information processing. 
The clustering coefficient of the white node 
would be 0.33, as 1 connection of the 3 
possible exists.  
5. Path length Global, local Minimum number of connections to go 
from one node to another node. This is a 
measure of information integration, as 
through e.g., long range connections 
distant clusters can exchange 
information. 
The path length between the white and the 
black node would be 3.  
6. Betweenness 
centrality 
Global, local The number of shortest paths that run 
through a node. This is a centrality 
measure. 
The white node would have the highest 
betweenness centrality as all short paths run 
through this node. 
The network falls apart when  
this node is removed. 
7. γ normalised 
clustering 
coefficient 
Global Quantifies how the global clustering 
coefficient of an observed network 
deviates from that of a random network. 
 
8. λ normalised 
path length 
Global Quantifies how the global path length of 
an observed network deviates from that 
of a random network. 
 
9. Small world 
property 
Global An observed network with γ > 1 and λ ≈ 
1 is ‘small world’, i.e., a network 
balances specialised information 
processing through clustering and 
information integration through long 
range connections. In a random network 
path length (L) is minimised, at the 
expense of a loss of clustering (C). In 
contrast a completely regularly organised 
network has high clustering, at the expe-
nse of the highest path length value. 
 











Table 2. Baseline clinical and grey matter network characteristics by clinical progression for non-demented memory 
clinic subjects with abnormal Aβ42 CSF markers (cut-off <640 pg/ml). 
 Stable Progression 
N (% of total sample) 100 (45%) 122 (55%) 
Baseline diagnosis MCI, n (%) 61 (61%) 99 (81%) 
b
 
Follow up diagnosis MCI, n (%) n.a. 17 (14 %) 
Follow up diagnosis AD dementia n.a. 98 (80%) 
Follow up diagnosis non-AD dementia n.a. 7 (6%) 
Female, n (%) 48 (48%) 61 (50%) 
Age years, mean (SD) 67 (8) 68 (8) 
Education, median (IQR) ’ 6 (5-6) 5 (4-6) 
MMSE, median (IQR) 28 (27-29) 27 (25-28) 
b
 
T-tau pg/ml, median (IQR) 365 (223-564) 540 (372-803) 
b
 
Ptau pg/ml, median (IQR) 56 (38-79) 78 (65-108) 
b
 
Follow-up time years, median (IQR) 2.3 (1.4-3.1) 2.2 (1.3-3.1) 
Normalised whole brain grey matter volume, mean (SD) 
§
 0.42 (.04) 0.40 (.05) 
a
 
Network size, mean (SD) 6922 (669) 6822 (706) 
Degree, mean (SD) 1129 (126) 1118 (135) 
% connections, mean (SD) 16 (1) 16 (1) 
Clustering, mean (SD) 0.465 (0.024) 0.463 (0.024) 
Path length, mean (SD) 2.02 (0.02) 2.01 (0.02) 
Betweenness centrality, mean (SD) 7037.47 (715.53) 6906.57 (715.88) 
γ, mean (SD) 1.68 (0.08) 1.65 (0.1) a 
λ, mean (SD) 1.1 (0.01) 1.1 (0.01) 
Small world, mean (SD) 1.53 (0.06) 1.50 (0.07) 
a
 
% were calculated according to clinical status unless specified otherwise, n.a. is not applicable, MCI is mild cognitive 
impairment, AD is Alzheimer’s disease, MMSE is mini-mental state examination, Aβ is amyloid beta, SD is standard 
deviation, IQR is inter quartile range,
 §
 whole brain grey matter volume was normalized by total intracranial volume, 
γ is normalised clustering coefficient, λ is normalised path length. ‘ data missing for N = 4. Groups were compared 
using Student’s t test, Kruskal tests or chi square tests where appropriate, and for network measures ANCOVAs were 
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used adjusting for baseline diagnosis, age, gender, normalised whole brain grey matter volume, and scanner type, 
a
 is 
p < .01, 
b




Table 3. Hazard Ratios (95%CI) of Cox proportional hazards analysis of grey matter network property values to 
predict time to clinical progression in non-demented subjects with abnormal amyloid. 
Network property Model 1 Model 2  Model 3 Model 4 
Network size, mean 
(SD) 
1.04 (0.82 - 1.32) 0.58 (0.32 – 1.06) 0.89 (0.46 – 1.72) 0.70 (0.37 – 1.35) 
Degree, mean (SD) 0.91 (0.72 - 1.15) 0.94 (0.74 – 1.20) 1.15 (0.88 – 1.50) 1.12 (0.86 – 1.46) 
% Connections, mean 
(SD) 
0.74 (0.56 - 0.97) 
a
 0.75 (0.56 – 0.99) a 0.82 (0.61 – 1.09) 0.76 (0.57 – 1.01) 
Clustering’ 0.29 (0.12 - 0.70) b 0.30 (0.12 – 0.71) b 0.32 (0.13 – 0.78) b 0.38 (0.16 – 0.91) a 
Path length’ 0.75 (0.56 - 0.99) a 0.69 (0.52 – 0.92) b 0.71 (0.53 – 0.95) b 0.75 (0.56 – 1.00) a 
Betweenness 
centrality’ 
1 (0.78 - 1.27) 1.02 (0.79 – 0.92) 1.24 (0.94 – 1.63) 1.29 (0.98 – 1.70)  
γ’ 0.67 (0.52 - 0.88) b 0.65 (0.50 – 0.85) b 0.70 (0.53 – 0.91) b 0.71 (0.54 – 0.93) b 
λ’ 0.75 (0.57 - 0.99) a 0.70 (0.53 - 0.92) b 0.72 (0.55 – 0.95) b 0.76 (0.57 – 1.00) a 
Small world ’ 0.68 (0.53 - 0.88) b 0.67 (0.51 - 0.86) b 0.71 (0.55 – 0.93) b 0.72 (0.55 – 0.94) c 
γ is normalised clustering coefficient, λ is normalised path length. All measures were Z transformed and so e.g., 
Hazard Ratio = .30 means a standard deviation decrease in a network property value is associated with about a 3-
fold risk to clinically progress. Model 1: network predictor + age + gender + normalised grey matter volume + 
baseline diagnosis + scanner type; Model 2: Model 1 + CSF tau levels; Model 3: Model 2 + hippocampal volume; 
Model 4: Model 3 + MMSE. Variables indicated with ‘ were additionally corrected for connectivity density in all 
models. 
a
 is p <.05, 
b




 Abnormal amyloid is predictive for dementia, but does not predict when. 
 Grey matter network alterations were associated with clinical progression 
 Low clustering values were associated with 3 fold increased risk to progress 
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